On Tuesday Dr. Steven Hatfill, infectious disease expert, blamed Dr. Fauci and Dr. Janet Woodcock for hundreds of thousands of deaths because they panned the use of hydroxychloroquine for patients in the early stages of COVID-19.
This despite numerous tests which all showed great progress in the early stages. But, I fear this had more to do about politics than it did medicine. Trump lauded it, so they had to say it was bad.
Even in its latest stages it was still effective 28% of the time but in its earliest stages its rating jumped to 65% and it was 72% in early mortality rates.
Imagine if we had not been the only country to fearmonger the use of the drug simply because they did not want President Trump to look good for touting it. And just look at the sample size. 232 trials, 3,706 doctors and 358,764 patients. That’s a huge sampling.
He emphasized that Dr. Fauci has “lied to the American people” by insisting that authorizing a treatment for COVID-19 rests on “controlled trials to get anything through the FDA.”
“That is not true. That has never been the historical precedent and almost no other medication has ever had to meet those standards,” Dr. Zelenko continued.
Dr Hatfill said:
“You don’t need a vaccine.”
“It’s quite evident that Dr. Fauci, Dr. Woodcock, Dr. [Rick] Bright are responsible for hundreds of thousands of America deaths for causing this drug to pick up a bad name.”
Dr Janet Woodcock is also responsible.
Documents from an administrative proceeding filed by former HHS Biomedical Advanced Research and Development Authority Director Rick Bright say Azar initially asked that the drug be made available under an “expanded access” (EA) protocol, typically used for drugs that haven’t yet received FDA approval, which hydroxychloroquine has. Also called “compassionate use,” that approach allows patients with severe illnesses to try unapproved drugs when no other treatments are available.
Bright and Food and Drug Administration Center for Drug Evaluation and Research Director Janet Woodcock pushed back on Azar’s request, the complaint said, and the FDA opted for the emergency use authorization. Expanded access can be applied more broadly and the planned protocol would have made the drug available for treatment of Covid-19 outside of a hospital setting.
Click this link for the original source of this article.
Author: Steven Ahle
This content is courtesy of, and owned and copyrighted by, https://davidharrisjr.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.